Skip to main content
SpringerLink
Log in

Health care costs and their predictors of inflammatory bowel diseases in Germany

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Objectives

Detailed cost studies of inflammatory bowel diseases (IBD) for Germany are limited. Aim of this study was to collect resource-use data related to IBD via a cross-sectional study, to quantify these from the perspective of the Statutory Health Insurance (SHI) and to identify cost-driving factors.

Methods

Patients with Crohn’s disease (CD) or ulcerative colitis (UC) from 24 gastroenterological specialists’ practices and two hospitals were enrolled in an internet-based database between March 2006 and July 2007. Outpatient services, inpatient visits as well as medication usage were recorded and evaluated from the perspective of the SHI for 2007. Disease severity was measured by the Crohn’s Disease Activity Index (CDAI) and the Colitis Activity Index (CAI), respectively. Extensive statistical analyses including generalized linear modeling (gamma model with the log link) to identify cost-driving factors were performed.

Results

Data from 1,030 patients with IBD (CD: 511; UC: 519) were collected. On average a patient with CD incurs annual costs of EUR 3,767 (±5,895 (SD)) (among those 68.5% medication; 20.5% inpatient) and an average patient with UC incurs EUR 2,478 (±4,591) (74% medication; 10% inpatient), whereas 10% of the patient with IBD account for 49% (CD: 50%; UC: 46%) of the costs. The regression analysis showed that especially the use of TNF-alpha-inhibitors, inpatient stays, gender as well as the severity status has a significant influence on costs. Further disease-specific impact factors were identified.

Conclusions

This is the first study to calculate costs due to CD and UC from the perspective of the SHI in Germany and to identify cost-driving factors. It confirms a high economic burden of IBD to payers and society.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Crohn, B.B., Ginzburg, L., Oppenheimer, G.D.: Regional ileitis—a pathologic and clinical entity. JAMA 99, 1323–1329 (1932)

    Google Scholar 

  2. Baumgart, D.C., Sandborn, W.J.: Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369, 1641–1657 (2007)

    Article  PubMed  CAS  Google Scholar 

  3. Bokemeyer, B.: IBD-treatment in Germany. Gastroenterologe 2, 447–455 (2007)

    Article  Google Scholar 

  4. Brandes, J.W., Lorenz-Meyer, H.: Epidemiologic aspects of Crohn regional enterocolitis and ulcerative colitis in Marburg/Lahn (West Germany) between 1962 and 1975. Z. Gastroenterol. 21, 69–78 (1983)

    PubMed  CAS  Google Scholar 

  5. Daiss, W., Scheurlen, M., Malchow, H.: Epidemiology of inflammatory bowel disease in the county of Tubingen (West Germany). Scand. J. Gastroenterol. Suppl. 170, 39–43 (1989)

    Article  PubMed  CAS  Google Scholar 

  6. Goebell, H., Dirks, E., Förster, S., et al.: A prospective analysis of the incidence and prevalence of Crohn’s disease in an urban population in Germany. Eur. J. Gastroenterol. Hepatol. 6, 1039–1045 (1994)

    Article  Google Scholar 

  7. Federal Statistical Office: Costs of illness accounts. Wiesbaden (2008)

  8. Beiche, A., Konig, H.H., Ebinger, M., et al.: Costs of ambulant care for patients with inflammatory bowel disease in general practice. Z. Gastroenterol. 41, 527–536 (2003)

    Article  PubMed  CAS  Google Scholar 

  9. Blumenstein, I., Bock, H., Weber, C., et al.: Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: a multicenter, prospective, internet-based study. Inflamm. Bowel Dis. 14, 53–60 (2008)

    Article  PubMed  CAS  Google Scholar 

  10. Ebinger, M., Leidl, R., Thomas, S., et al.: Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. J. Gastroenterol. Hepatol. 19, 192–199 (2004)

    Article  PubMed  Google Scholar 

  11. Rösch, M., Leidl, R., Thomas, S., et al.: Measurement of outpatient treatment costs of chronic inflammatory bowel diseases at a German university hospital. Med Klin (Munich) 97, 128–136 (2002)

    Article  Google Scholar 

  12. Stark, R., Konig, H.H., Leidl, R.: Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 24, 797–814 (2006)

    Article  PubMed  Google Scholar 

  13. Rösch, M., Leidl, R., von Tirpitz, C., et al.: Cost measurement based on a cost diary in patients with inflammatory bowel disease. Z. Gastroenterol. 40, 217–228 (2002)

    Article  PubMed  Google Scholar 

  14. Best, W.R., Becktel, J.M., Singleton, J.W., et al.: Development of a Crohn’s disease activity index. National cooperative Crohn’s disease study. Gastroenterology 70, 439–444 (1976)

    PubMed  CAS  Google Scholar 

  15. Rachmilewitz, D.: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298, 82–86 (1989)

    Article  PubMed  CAS  Google Scholar 

  16. Braun, S., Prenzler, A., Mittendorf, T., et al.: Appraisal for the valuation of resource use in the German health-care system from the perspective of the statutory health insurance. Gesundheitswesen 71, 19–23 (2009)

    Article  PubMed  CAS  Google Scholar 

  17. National Association of Statutory Health Insurance Physicians: Appendix 3 regarding the resolution of the assessment committee according to § 87 para. 1 SGB V for determining the standard service volumes by the Associations of Statutory Health Insurance Physicians according to § 85 para. 4a SGB V. (2008)

  18. Hoffmann, J.C., Preiss, J.C., Autschbach, F., et al.: Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z. Gastroenterol. 46, 1094–1146 (2008)

    Article  PubMed  CAS  Google Scholar 

  19. Federal Statistical Office: Diagnosis data of patients in hospitals 2006, Fachserie 12 Reihe 6.2.1. Wiesbaden (2008)

  20. InEK GmbH—Institute for the Hospital Remuneration System: G-DRG Definition Handbook, Version 2007. Siegburg (2006)

  21. Federal Association of Local Health Care Funds: Overview of the case values in the single federal states (2007)

  22. InEK GmbH—Institute for the Hospital Remuneration System: Diagnosis Related Group-Catalogue 2007 (2006)

  23. LAUER-FISCHER GmbH. Lauer-Taxe online (www.lauer-fischer.de)

  24. Dodd, S., Bassi, A., Bodger, K.: A comparison of multivariable regression models to analyse cost data. J. Eval. Clin. Pract. 12, 76–86 (2006)

    Article  PubMed  Google Scholar 

  25. Nixon, R.M., Thompson, S.G.: Parametric modelling of cost data in medical studies. Stat. Med. 23, 1311–1331 (2004)

    Article  PubMed  CAS  Google Scholar 

  26. O’Hagan, A., Stevens, J.W.: Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality? Health Econ. 12, 33–49 (2003)

    Article  PubMed  Google Scholar 

  27. Briggs, A., Nixon, R., Dixon, S., et al.: Parametric modelling of cost data: some simulation evidence. Health Econ. 14, 421–428 (2005)

    Article  PubMed  Google Scholar 

  28. Gibson, T.B., Ng, E., Ozminkowski, R.J., et al.: The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J. Occup. Environ. Med. 50, 1261–1272 (2008)

    Article  PubMed  Google Scholar 

  29. Hillson, E., Dybicz, S., Waters, H.C., et al.: Health care expenditures in ulcerative colitis: the perspective of a self-insured employer. J. Occup. Environ. Med. 50, 969–977 (2008)

    Article  PubMed  Google Scholar 

  30. Odes, S., Vardi, H., Friger, M., et al.: Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 131, 719–728 (2006)

    Article  PubMed  Google Scholar 

  31. Yu, A.P., Cabanilla, L.A., Wu, E.Q., et al.: The costs of Crohn’s disease in the United States and other Western countries: a systematic review. Curr. Med. Res. Opin. 24, 319–328 (2008)

    Article  PubMed  CAS  Google Scholar 

  32. Odes, S.: How expensive is inflammatory bowel disease? A critical analysis. World J. Gastroenterol. 14, 6641–6647 (2008)

    Article  PubMed  Google Scholar 

  33. Kappelman, M.D., Rifas-Shiman, S.L., Porter, C.Q., et al.: Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology 135, 1907–1913 (2008)

    Article  PubMed  Google Scholar 

  34. Henriksen, M., Jahnsen, J., Lygren, I., et al.: Clinical course in Crohn’s disease: results of a five-year population-based follow-up study (the IBSEN study). Scand. J. Gastroenterol. 42, 602–610 (2007)

    Article  PubMed  Google Scholar 

  35. Solberg, I.C., Lygren, I., Jahnsen, J., et al.: Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand. J. Gastroenterol. 44, 431–440 (2009)

    Article  PubMed  Google Scholar 

  36. Holtmann, M.H., Krummenauer, F., Claas, C. et al.: Significant differences between Crohn’s disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a european multicenter study in 1,176 patients. Dig. Dis. Sci. 55, 1066–1078 (2010)

    Google Scholar 

  37. Brechmann, T., Schmiegel, W.: Procedure of implementation of new methods of examination and treatment in the G-DRG system (NUB procedure). Med. Klin. (Munich) 102, 683–684 (2007)

    Article  Google Scholar 

  38. von der Schulenburg, J.-M., Greiner, W., Jost, F., et al.: German recommendations on health economic evaluation: third and updated version of the Hanover consensus. Value Health 11, 539–544 (2008)

    Article  Google Scholar 

  39. Häussler, B., Höer, A., Hempel, E. et al.: Arzneimittel-Atlas 2009: Der Arzneimittelverbrauch in der GKV. Munich. (2009)

Download references

Conflict of interest

No funding was received for the cost analysis or writing of this manuscript.

Author information

Authors and Affiliations

  1. Leibniz University Hannover, Center for Health Economics, Koenigsworther Platz 1, 30167, Hannover, Germany

    Anne Prenzler, J.-Matthias von der Schulenburg & Thomas Mittendorf

  2. Gastroenterology Practice Minden, Minden, Germany

    Bernd Bokemeyer

Authors
  1. Anne Prenzler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernd Bokemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J.-Matthias von der Schulenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Mittendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne Prenzler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prenzler, A., Bokemeyer, B., von der Schulenburg, JM. et al. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ 12, 273–283 (2011). https://doi.org/10.1007/s10198-010-0281-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-010-0281-z

Keywords

JEL Classification

Search

Navigation